IVIG (Gamunex-C) Treatment Study for POTS Subjects

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

October 29, 2018

Primary Completion Date

June 26, 2023

Study Completion Date

December 1, 2023

Conditions
Postural Tachycardia Syndrome
Interventions
DRUG

IVIG

"If you participate in this study there will be 18 scheduled treatment infusions during the 30 week study period. All the study visits and treatment visits will be outpatient visits.~Once you qualify to participate in the study and begin treatment, there will be two 12 week treatment periods separated by a 6 week washout period. The infusion visits will take approximately 3-4 hours each."

DRUG

Albumin

This will be the matching placebo used in the study.

Trial Locations (1)

75208

UT Southwestern Medical Center, Dallas

Sponsors
All Listed Sponsors
collaborator

Grifols Biologicals, LLC

INDUSTRY

collaborator

Dysautonomia International

OTHER

lead

University of Texas Southwestern Medical Center

OTHER

NCT03919773 - IVIG (Gamunex-C) Treatment Study for POTS Subjects | Biotech Hunter | Biotech Hunter